Abstract:We developed a custom-designed liposome carrier for codelivery of a potent immunogenic cell death (ICD) stimulus plus an inhibitor of the indoleamine 2,3-dioxygenase (IDO-1) pathway to establish a chemo-immunotherapy approach for solid tumors in syngeneic mice. The carrier was constructed by remote import of the anthraquinone chemotherapeutic agent, mitoxantrone (MTO), into the liposomes, which were further endowed with a cholesterol-conjugated indoximod (IND) prodrug in the lipid bilayer. For proof-of-principle testing, we used IV injection of the MTO/IND liposome in a CT26 colon cancer model to demonstrate the generation of a robust immune response, characterized by the appearance of ICD markers (CRT and HMGB-1) as well as evidence of cytotoxic cancer cell death, mediated by perforin and granzyme B. Noteworthy, the cytotoxic effects involved natural killer (NK) cell, which suggests a different type of ICD response. The immunotherapy response was significantly augmented by codelivery of the IND prodrug, which induced additional CRT expression, reduced number of Foxp3+ Treg, and increased perforin release, in addition to extending animal survival beyond the effect of an MTO-only liposome. The outcome reflects the improved pharmacokinetics of MTO delivery to the cancer site by the carrier. In light of the success in the CT26 model, we also assessed the platform efficacy in further breast cancer (EMT6 and 4T1) and renal cancer (RENCA) models, which overexpress IDO-1. Encapsulated MTO delivery was highly effective for inducing chemo-immunotherapy responses, with NK participation, in all tumor models. Moreover, the growth inhibitory effect of MTO was enhanced by IND codelivery in EMT6 and 4T1 tumors. All considered, our data support the use of encapsulated MTO delivery for chemo-immunotherapy, with the possibility to boost the immune response by codelivery of an IDO-1 pathway inhibitor.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c05194?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c05194</a>.Additional figures and results, e.g., NMR, MS, HPLC spectra, and representative IHC staining, as described in the text (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c05194/suppl_file/nn0c05194_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Capturing Hydrophilic Chemotherapeutics Agents Into siRNA‐Encapsulated Vesicle‐Like Nanoparticles for Convenient ICB‐Chemo Combination Therapy

A siRNA-Assisted Assembly Strategy to Simultaneously Suppress “Self” and Upregulate “Eat-Me” Signals for Nanoenabled Chemo-Immunotherapy

Combination Antitumor Immunotherapy with VEGF and PIGF Sirna Via Systemic Delivery of Multi-Functionalized Nanoparticles to Tumor-Associated Macrophages and Breast Cancer Cells

Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy

GSH-responsive camptothecin prodrug-based hybrid micellar nanoparticles enable antitumor chemo-immunotherapy by PD-L1 knockdown

Tumor microenvironment-activated cancer cell membrane-liposome hybrid nanoparticle-mediated synergistic metabolic therapy and chemotherapy for non-small cell lung cancer

Nanoassembly of doxorubicin-conjugated polyphosphoester and siRNA simultaneously elicited macrophage- and T cell- mediated anticancer immune response for cancer therapy

Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells.

Simultaneous Delivery of Sirna and Paclitaxel Via a "Two-in-one" Micelleplex Promotes Synergistic Tumor Suppression.

CaCO3-complexed pH-responsive nanoparticles encapsulating mitoxantrone and celastrol enhance tumor chemoimmunotherapy

Clinical Chemotherapeutic Agent Coordinated Copper‐Based Nanoadjuvants for Efficiently Sensitizing Cancer Chemo‐Immunotherapy by Cuproptosis‐Mediated Mitochondrial Metabolic Reprogramming

Quick Synthesis of a Novel Combinatorial Delivery System of Sirna and Doxorubicin for a Synergistic Anticancer Effect

CaCO 3 -complexed pH-responsive nanoparticles encapsulating mitoxantrone and celastrol enhance tumor chemoimmunotherapy

A Supramolecular Co-Delivery Strategy for Combined Breast Cancer Treatment and Metastasis Prevention

Cancer-cell-membrane-camouflaged Supramolecular Self-Assembly of Antisense Oligonucleotide and Chemodrug for Targeted Combination Therapy

Erythrocyte Membrane Camouflaged Sirna/chemodrug Nanoassemblies for Cancer Combination Therapy.

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

Integrated Combination Treatment Using a "smart" Chemotherapy and MicroRNA Delivery System Improves Outcomes in an Orthotopic Colorectal Cancer Model

Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Design of Mitoxantrone‐Loaded Biomimetic Nanocarrier with Sequential Photothermal/Photodynamic/Chemotherapy Effect for Synergized Immunotherapy